Actively Recruiting
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Led by Novartis Pharmaceuticals · Updated on 2025-08-03
2382
Participants Needed
20
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
CONDITIONS
Official Title
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- Male or female aged 18 years or older
- Have had one of the following Atherosclerotic Cardiovascular Diseases for at least 3 months within the last 2 years: history of heart attack, ischemic stroke or transient ischemic attack, ischemic heart disease confirmed by coronary angiography with 50% or more stenosis, any revascularization surgery including CABG, PCI, carotid endarterectomy or stenting, or peripheral artery disease with specific clinical signs
You will not qualify if you...
- Acute infectious or inflammatory diseases such as COVID-19 within 1 month before screening
- Previous treatment with Lp(a)-lowering therapies including Lp(a) apheresis, PCSK9 inhibitors, or inclisiran before screening
- Participation in any interventional clinical study with investigational or marketed medicines at enrollment
- Participation in other real-world clinical studies
- Stage 4 or 5 chronic kidney disease or significant liver disease based on specified laboratory values
- Other protocol-defined exclusion criteria that may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Novartis Investigative Site
Chelyabinsk, Russia, 454048
Actively Recruiting
2
Novartis Investigative Site
Chelyabinsk, Russia, 454076
Actively Recruiting
3
Novartis Investigative Site
Kaluga, Russia, 248000
Actively Recruiting
4
Novartis Investigative Site
Kemerovo, Russia, 650002
Actively Recruiting
5
Novartis Investigative Site
Krasnoyarsk, Russia, 680022
Actively Recruiting
6
Novartis Investigative Site
Moscow, Russia, 119881
Actively Recruiting
7
Novartis Investigative Site
Moscow, Russia, 121552
Actively Recruiting
8
Novartis Investigative Site
Moscow, Russia, 125284
Actively Recruiting
9
Novartis Investigative Site
Omsk, Russia, 644024
Actively Recruiting
10
Novartis Investigative Site
Perm, Russia, 614002
Actively Recruiting
11
Novartis Investigative Site
Ryazan, Russia, 390039
Actively Recruiting
12
Novartis Investigative Site
Surgut, Russia, 628403
Actively Recruiting
13
Novartis Investigative Site
Tomsk, Russia, 634009
Actively Recruiting
14
Novartis Investigative Site
Tyumen, Russia, 625026
Actively Recruiting
15
Novartis Investigative Site
Vladimir, Russia, 600020
Actively Recruiting
16
Novartis Investigative Site
Vladivostok, Russia, 690000
Actively Recruiting
17
Novartis Investigative Site
Voronezh, Russia, 394018
Actively Recruiting
18
Novartis Investigative Site
Yakutsk, Russia, 677013
Actively Recruiting
19
Novartis Investigative Site
Yekaterinburg, Russia, 620137
Actively Recruiting
20
Novartis Investigative Site
Yekaterinburg, Russia, 620144
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here